Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司
(A joint stock company established in the People's Republic of China with limited liability)
(Stock Code: 9887)

VOLUNTARY ANNOUNCEMENT
LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) INCLUDED IN THE PRIORITY REVIEW AND APPROVAL PROCEDURE FOR THE TREATMENT OF ADVANCED EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC)

This announcement is made by Nanjing Leads Biolabs Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform shareholders and potential investors of the Company about the latest business development of the Company.

The Company is pleased to announce that the biologics license application (BLA) for LBL-024 (Opamtistomig, a PD-L1/4-1BB bispecific antibody) as monotherapy for the treatment of advanced extrapulmonary neuroendocrine carcinoma (EP-NEC) has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of the People's Republic of China for inclusion in the priority review and approval procedure. This BLA submission is based on the positive results from a pivotal registrational clinical study led by Professor Shen Lin (沈琳) of Beijing Cancer Hospital (北京腫瘤醫院), which was designed to evaluate the efficacy and safety of LBL-024 in patients with advanced EP-NEC whose disease had progressed following two or more prior lines of systemic therapy.

Under the relevant PRC regulations, the review timeline for a BLA included in the priority review and approval procedure is 130 working days, as compared with 200 working days under the ordinary review procedure. The inclusion of LBL-024 in the priority review process represents a key milestone toward its commercialization, providing clarity and visibility on its expected approval timeline. The Company is actively advancing relevant pre-launch commercialization preparations.

ABOUT EP-NEC

EP-NEC is a highly aggressive immunologically cold tumor for which no therapy has been approved by any regulatory authority worldwide. Platinum-based chemotherapy remains the standard first-line treatment for patients with advanced EP-NEC, with a median overall survival (mOS) of approximately one year. However, there are no effective treatment options following progression on first-line platinum-based chemotherapy. For patients who have received two or more prior lines of systemic therapy, currently available later-line treatment options provide very limited clinical benefit, with reported objective response rates (ORR) ranging from 0% to 10% and a mOS of only three to four months. As such, EP-NEC represents an area of substantial unmet medical need, underscoring the urgent need for new and effective treatment approaches.

ABOUT LBL-024 (OPAMTISTOMIG)

LBL-024 is a bispecific antibody simultaneously targeting PD-L1 and 4-1BB, and is a pan-tumor IO 2.0 cornerstone therapy with potential survival benefit. Leveraging our self-developed X-body™ platform with full intellectual property rights, LBL-024 achieves conditional activation of 4-1BB, relieving PD-1/PD-L1 immunosuppression while enhancing 4-1BB regulated T-cell activation, achieving a synergistic effect in eliminating tumors. LBL024 demonstrates a safety profile comparable to PD-1/PD-L1 inhibitors and greater potential for broad-spectrum cancer treatment, and has demonstrated first-in-class (FIC) or best-in-class (BIC) potential in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), extrapulmonary neuroendocrine carcinoma (EP-NEC) and biliary tract cancer (BTC).

As the first molecule targeting the co-stimulatory receptor 4-1BB to have reached the pivotal single-arm registrational clinical stage globally, LBL-024 has the potential to become the first drug approved for treating EP-NEC. LBL-024 has initiated clinical studies across 13 solid tumor indications in China, including one pivotal registrational clinical study and eight proof-of-concept studies, covering EP-NEC, NSCLC, SCLC, BTC, ovarian cancer (OC), esophageal squamous cell carcinoma (ESCC), hepatocellular carcinoma (HCC), gastric cancer (GC), triple-negative breast cancer (TNBC) and melanoma, among other areas with high unmet medical needs.

4-1BB, as an agonist, can reactivate apoptotic T cells and induce substantial proliferation, making it suitable for treating "cold tumors" that are resistant or unresponsive to PD-1/PD-L1 therapies. LBL-024 received the Breakthrough Therapy Designation (BTD) from CDE of the NMPA in October 2024, as well as the Orphan Drug Designation in treating neuroendocrine carcinoma (NEC) from the FDA in November 2024. In January 2026, LBL-024 received Fast Track Designation (FTD) from the FDA for the treatment of EP-NEC and Orphan Drug Designation from the European Union.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop, or ultimately market, LBL-024, successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司
Dr. KANG XIAOQIANG
Chairman, Executive Director and Chief Executive Officer

Nanjing, PRC, July 10, 2026

As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Kang Xiaoqiang (Chairman of the Board), Dr. Lai Shoupeng and Mr. Zuo Honggang as executive Directors; (ii) Mr. Zhang Yincheng, Dr. Chen Renhai and Dr. Wu Fenglan as non-executive Directors; and (iii) Dr. Zhang Hongbing, Mr. Du Yilong and Ms. Du Jiliu as independent non-executive Directors.